Navigating South Korea’s MFDS Regulatory Requirements for Indian API Manufacturers despite holding USFDA approval

Authors

  • Leemol Varghese Associate Professor, Department of Pharmacognosy, Sarojini NaiduVanita Pharmacy Maha Vidyalaya (Co-Ed.), (Affiliated to Osmania University), Hyderabad, Telangana, India.
  • Sai Sree Sakinala Student, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.),Affliated to Osmania University, Hyderabad ,India.
  • Abhilash Gattu Assistant Manger, Exports, Leads Pharma Ltd, Hyderabad.
  • Ashwitha Erukulla Student, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya (Co-Ed.),Affliated to Osmania University, Hyderabad ,India.
  • Medishetti Swetha Associate Professor&Head, Department of Regulatory Affairs, Sarojini NaiduVanita Pharmacy Maha Vidyalaya (Co-Ed.), (Affiliated to Osmania University), Hyderabad, Telangana, India.

Keywords:

Good Manufacturing Practice, Regulatory Compliance, Technical Dossier Consistency, Ministry of Food and Drug Safety, PIC/S

Abstract

Many Indian pharmaceutical companies have built strong track records supplying Active Pharmaceutical Ingredients (APIs) to the United States and navigating USFDA inspections. However, having a smooth USFDA history doesn’t automatically mean South Korea’s Ministry of Food and Drug Safety (MFDS) will fast-track your product. Even though global guidelines like PIC/S and ICH help bring countries closer together on standards, South Korea still has its own unique laws, filing steps, and evidence rules. This article looks at why Indian manufacturers with solid quality systems can still hit roadblocks or face unexpected questions when trying to break into the South Korean market. Often, the issue comes down to differences in inspection scopes, evidence packages, supply chains, and specific product processes. To bridge the gap, companies need to focus closely on data integrity, impurity controls, starting-material traceability, validation, and change management. Success ultimately relies on doing your homework early, keeping your technical dossiers completely aligned with day-to-day manufacturing, and working closely with local Korean applicants.

Downloads

Download data is not yet available.

References

1. Ministry of Food and Drug Safety (MFDS), Republic of Korea. “Approval Process — Drugs.” Available from: https://mfds.go.kr/eng/wpge/m_17/de011008l001.do .

2. Ministry of Food and Drug Safety (MFDS), Republic of Korea. “Regulation on the Registration of Active Pharmaceutical Ingredient” Available from: https://www.mfds.go.kr/eng/brd/m_18/view.do?seq=71515 .

3. U.S. Food and Drug Administration (FDA). “Is It Really ‘FDA Approved’?” Consumer Update. Available from: https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved .

4. U.S. Food and Drug Administration (FDA). “Pharmaceutical Inspections and Compliance.” Available from: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/pharmaceutical-inspections-and-compliance .

5. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). “Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.” Available from: https://www.ich.org/page/quality-guidelines

6. Pharmaceutical Inspection Co-operation Scheme (PIC/S). “PIC/S” official website and guidance resources. Available from: https://picscheme.org/ .

7. U.S. Food and Drug Administration (FDA). “Current Good Manufacturing Practice Declarations.” Available from: https://www.fda.gov/drugs/human-drug-exports/current-good-manufacturing-practice-declarations .

8. Prasanna Gayathri B , Kamaraj R. Pharmaceutical Inspection Co-operation Scheme: An Overview.The Cureus Journal of Medical Science.2024, 6(9), DOI: 10.7759/cureus.69043

9. Kim Jeong-yeon, Kwon Kyung-hee. Comparative Study of Pharmaceutical Inspection Cooperation Scheme (PIC/S) and Korea's GMP for Securing International Quality Competitiveness of Pharmaceuticals.Journal of the Korean Pharmaceutical Society 2013,57(6), 432-441, DOI:10.7354/yk.2013.57.6.432

Downloads

Published

2026-11-07

How to Cite

Leemol, V., Sakinala, S. S., Gattu, A., Erukulla, A., & Medishetti, S. (2026). Navigating South Korea’s MFDS Regulatory Requirements for Indian API Manufacturers despite holding USFDA approval. Journal of Comprehensive Pharmaceutical Sciences , 1(2), 40–45. Retrieved from https://cognixpress.in/index.php/jcps/article/view/89

Issue

Section

Articles